Mehmet Yildiz1, Kerim Esenboğa2, Ahmet Afşin Oktay3. 1. Department of Medicine, Southern Ohio Medical Center, Portsmouth, Ohio, USA. 2. Department of Cardiology, Faculty of Medicine, Ankara University, Ankara, Turkey. 3. Division of Cardiology, Department of Medicine, Wentworth-Douglass Hospital, Partners HealthCare, Dover, New Hampshire, USA.
Abstract
PURPOSE OF REVIEW: Herein, we provide a review of the recent literature on the epidemiological and pathophysiological relationship between hypertension (HTN) and diabetes mellitus, along with prognostic implications and current treatment concepts. RECENT FINDINGS: Diabetes mellitus affects ∼10% of US adults. The prevalence of HTN in adults with diabetes mellitus was 76.3% or 66.0% based on the definitions used by guidelines. There exist differences among major society guidelines regarding the definition of HTN and target blood pressure (BP) levels. Recent basic and clinical research studies have shed light on pathophysiologic and genetic links between HTN and diabetes mellitus. Randomized controlled trials over the past 5 years have confirmed the favorable BP and cardiovascular risk reduction by antidiabetic agents. SUMMARY: HTN and diabetes mellitus are 'silent killers' with rising global prevalence. The development of HTN and diabetes mellitus tracks each other over time. The coexistence of both clinical entities synergistically contributes to micro- and macro-vasculopathy along with cardiovascular and all-cause mortality. Various shared mechanisms underlie the pathophysiological relationship between HTN and diabetes mellitus. Moreover, BP reduction with lifestyle interventions and antihypertensive agents is a primary target for reducing cardiovascular risk among patients with HTN and diabetes mellitus.
PURPOSE OF REVIEW: Herein, we provide a review of the recent literature on the epidemiological and pathophysiological relationship between hypertension (HTN) and diabetes mellitus, along with prognostic implications and current treatment concepts. RECENT FINDINGS:Diabetes mellitus affects ∼10% of US adults. The prevalence of HTN in adults with diabetes mellitus was 76.3% or 66.0% based on the definitions used by guidelines. There exist differences among major society guidelines regarding the definition of HTN and target blood pressure (BP) levels. Recent basic and clinical research studies have shed light on pathophysiologic and genetic links between HTN and diabetes mellitus. Randomized controlled trials over the past 5 years have confirmed the favorable BP and cardiovascular risk reduction by antidiabetic agents. SUMMARY: HTN and diabetes mellitus are 'silent killers' with rising global prevalence. The development of HTN and diabetes mellitus tracks each other over time. The coexistence of both clinical entities synergistically contributes to micro- and macro-vasculopathy along with cardiovascular and all-cause mortality. Various shared mechanisms underlie the pathophysiological relationship between HTN and diabetes mellitus. Moreover, BP reduction with lifestyle interventions and antihypertensive agents is a primary target for reducing cardiovascular risk among patients with HTN and diabetes mellitus.
Authors: Nasrin S Saiyed; Umar Yagoub; Bandar Al Qahtani; Attiya Mohammed Al Zahrani; Ibrahim Al Hariri; Meerab Javed Syed; Mohammed Elmujtaba Elmardi; Muhammad Abdullah Tufail; Marwan Manajreh Journal: J Multidiscip Healthc Date: 2022-07-27
Authors: Cristóbal Morales; Juan Francisco Merino-Torres; Paloma Moreno-Moreno; María Lainez; Iñigo Tejado; Alfredo Yoldi; Sonsoles Gutiérrez Medina; Alfonso Soto; Manuel A Botana; Virginia Bellido; Irene Caballero Journal: Drugs Context Date: 2022-02-17
Authors: Julia Simões Corrêa Galendi; Renata Giacomini Occhiuto Ferreira Leite; Luísa Rocco Banzato; Vania Dos Santos Nunes-Nogueira Journal: Int J Environ Res Public Health Date: 2022-04-02 Impact factor: 3.390